Pluristyx, a provider of tools, technologies, and services for cell therapies, has released its cryopreservation medium solution, PluriFreeze. Currently available in a Research Use Only (RUO) formulation, with a Good Manufacturing Practice (GMP) version to be released in future, PluriFreeze adds to the company’s Pluristyx’s panCELLa Platform for iPSC therapeutic development, with broad applicability for other sensitive cell types.
 
PluriFreeze is designed to support cell metabolism and ease pluripotent stem and other energetically active cells to and from the frozen state to enhance post-thaw viability and function. PluriFreeze offers benefits for cell therapy development that include an entirely synthetic and Animal-Origin Free (AOF) composition, low viscosity for automation and large-scale cell production, and a companion DMSO-free PluriPrep wash solution to enable extended processing times. Additionally, PluriFreeze is formulated with components Generally Recognized As Safe (GRAS) by the U.S. Federal Food, Drug, and Cosmetic Act.   
 
Ben Fryer, CEO of Pluristyx, said, “Our goal as an organization is to be a problem-solving partner for our customers, and one of the long-standing challenges for cell therapy developers has been the availability of high-performing, scalable, and cost-effective cryopreservation formulations. The launch of PluriFreeze represents a significant step forward in our commitment to providing comprehensive solutions for iPSCs with an entirely synthetic and AOF workflow. The strong compatibility of PluriFreze with our PluriBank, clinical-grade, pre-edited iPSCs, allows us to offer an integrated approach to our customers.”